PAVmed Inc.
PAVMPAVmed Inc. in brief
PAVmed Inc. is a listed company in the Medical Devices industry, based in New York, New York, USA. Its market value was $16 M on 30 October 2026, which makes it the 24,987th largest listed company in the world and the 4,207th largest in the USA on this site. It employs about 41 people and Lishan Aklog is its chief executive. Its shares trade under the symbol PAVM (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About PAVmed Inc.
PAVmed is a diversified commercial-stage life sciences company operating in the medical device, diagnostics, and digital health sectors. It operates through multiple independently financed subsidiaries under a shared services model. The Company’s strategy is to advance and commercialize innovative healthcare technologies through its subsidiaries while maintaining flexibility to structure financing at either the PAVmed level or within its subsidiaries.
The Company’s subsidiaries include Lucid Diagnostics, a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, of which the Company is the largest voting stockholder, and Veris Health, a majority-owned digital health company focused on improving personalized cancer care during treatment and throughout survivorship through digital health tools and the development of an implantable physiological monitor designed to interface with the Veris Cancer Care Platform.
From the company's annual report filed with the US SEC: read the report
PAVmed Inc. timeline
- 2014
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2015
- ✎Renamed PAVmed Inc.Formerly PAXmed Inc..
- 2016
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 29 January 2016; shares registered for exchange trading on 28 January 2016.
- 2024
- 💰Record revenue of $3 millionFY2024, the highest of the 4 years on record.
Events of PAVmed Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,174 (Jan 2020) · #3,561 (Jan 2021) · #3,935 (Jan 2022) · #4,836 (Dec 2022) · #4,882 (Jul 2023) · #4,232 (Jan 2024) · #2,331 (Mar 2026) · #3,809 (Aug 2026) · #4,102 (Oct 2026) · #4,209 (Oct 2026)
Key ratios
- P/E ratio
- 39.4×
- Price / sales
- —
- Price / book
- 0.5×
- Free cash flow yield
- -33.3%
- Net margin
- —
- Operating margin
- —
- Return on equity
- 1.2%
- Liabilities / assets
- 42.5%
- Revenue growth
- +20.0%
- R&D / revenue
- 197.7%
- Profit per employee
- $10 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-22M | $0M | — |
| Dec 2024 | $3M | +20.0% | $-44M | $40M | 1326.3% |
| Dec 2023 | $3M | +557.9% | $-69M | $-64M | -2567.2% |
| Dec 2022 | $0M | -24.0% | $-91M | $-89M | -23415.8% |
| Dec 2021 | $1M | — | $-54M | $-50M | -10070.0% |
| Dec 2020 | — | — | $-23M | $-34M | — |
| Dec 2019 | — | — | $-14M | $-16M | — |
| Dec 2018 | — | — | $-11M | $-18M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-5M | $0M | $-5M | $-5.63 | — |
| Dec 2024 | $-34M | $0M | $-34M | $14.90 | — |
| Dec 2023 | $-52M | $0M | $-52M | $-9.16 | — |
| Dec 2022 | $-71M | $2M | $-73M | $-15.03 | — |
| Dec 2021 | $-41M | $1M | $-42M | $-0.65 | — |
| Dec 2020 | $-22M | $0M | $-22M | $-0.72 | — |
| Dec 2019 | $-13M | $0M | $-13M | $-0.54 | — |
| Dec 2018 | $-9M | $0M | $-9M | $-0.81 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $0M (+200.0% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 22, 20268-KCurrent reportMaterial agreement
- Sep 10, 20268-KCurrent reportMaterial agreement
- Aug 14, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Jun 24, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 15, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- May 14, 202610-QQuarterly report · period to Mar 2026
- Apr 30, 2026DEF 14AProxy statement
- Mar 30, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Mar 27, 20268-KCurrent reportDirectors or officers changed · Bylaws amended · Shareholder vote
- Mar 27, 202610-KAnnual report · period to Dec 2025
- Feb 24, 2026DEF 14AProxy statement
Official filings of PAVmed Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-22 M
- Net income
- $0 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $39 M
- Total liabilities
- $17 M
- Total equity
- $34 M
As of December-2025
Top 24 institutional investors in PAVmed Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Two Seas Capital LP | 461,539 | 0 (0.00%) | 5.77% | $2 M | Oct 6, 2026 |
| 2 | First Manhattan Co. LLC. | 333,959 | +1,048 (+0.31%) | 4.18% | $1 M | Nov 16, 2026 |
| 3 | Vanguard Capital Management LLC | 63,207 | +1,603 (+2.60%) | 0.79% | $0 M | Nov 13, 2026 |
| 4 | Geode Capital Management, LLC | 29,466 | -7,212 (-19.66%) | 0.37% | $0 M | Nov 6, 2026 |
| 5 | Citadel Advisors LLC | 29,095 | New | 0.36% | $0 M | Nov 16, 2026 |
| 6 | Vanguard Fiduciary Trust Co | 25,605 | 0 (0.00%) | 0.32% | $0 M | Nov 13, 2026 |
| 7 | BlackRock, Inc. | 15,544 | -1,548 (-9.06%) | 0.19% | $0 M | Nov 13, 2026 |
| 8 | Pinnacle Financial Group, Inc. | 4,700 | — | 0.06% | $0 M | Nov 16, 2026 |
| 9 | Parkside Financial Bank & Trust | 246 | New | 0.00% | $0 M | Oct 27, 2026 |
| 10 | Royal Bank Of Canada | 216 | +215 (+21500.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 11 | Morgan Stanley | 160 | -3 (-1.84%) | 0.00% | $0 M | Nov 13, 2026 |
| 12 | SBI Securities Co., Ltd. | 67 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 13 | UBS Group AG | 51 | -6 (-10.53%) | 0.00% | $0 M | Nov 10, 2026 |
| 14 | Wells Fargo & Company/mn | 45 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 15 | Citigroup Inc | 9 | New | 0.00% | $0 M | Nov 4, 2026 |
| 16 | Allworth Financial LP | 6 | +1 (+20.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 17 | Osaic Holdings, Inc. | 4 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 18 | Strategic Financial Concepts, LLC | 4 | New | 0.00% | $0 M | Nov 16, 2026 |
| 19 | Federation des caisses Desjardins du Quebec | 4 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 20 | Steward Partners Investment Advisory, LLC | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 21 | BFC Planning, Inc. | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 22 | Jones Financial Companies Lllp | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 23 | Foresight Capital Management Advisors, Inc. | 1 | New | 0.00% | $0 M | Oct 27, 2026 |
| 24 | Caitong International Asset Management Co., Ltd | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding PAVmed Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 57,879 | $0 M | 0.72% | <0.01% | +878% | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 13,795 | $0 M | 0.17% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 6,189 | $0 M | 0.08% | <0.01% | +10% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 1,217 | $0 M | 0.02% | <0.01% | +74% | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 881 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 262 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 226 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at PAVmed Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Victoria Tou-ho LeeChief Medical Officer | Grant or award | +70,000 | — | — | 71,666 | Form 4 |
| filed | Lishan AklogChairman and CEO, Director | Grant or award | +350,000 | — | — | 357,614 | Form 4 |
| filed | Debra WhiteDirector | Grant or award | +13,930 | — | — | 21,097 | Form 4 |
| filed | Michael Adam GordonGeneral Counsel | Grant or award | +110,000 | — | — | 115,000 | Form 4 |
| filed | Michael J. GlennonDirector | Grant or award | +13,930 | — | — | 21,653 | Form 4 |
| filed | Ronald M. SparksDirector | Grant or award | +13,930 | — | — | 21,097 | Form 4 |
| filed | Timothy E. BaxterDirector | Grant or award | +13,930 | — | — | 21,097 | Form 4 |
| filed | Shaun O'NeilChief Operating Officer | Grant or award | +110,000 | — | — | 115,598 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: PAVmed Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2019 | Q4 2019 | $0M |
Trading halts
- 2026-07-23 15:21 UTC, code LUDP, resumed 15:36 UTC
- 2026-07-16 13:40 UTC, code LUDP, resumed 13:45 UTC
- 2026-06-18 19:53 UTC, code LUDP, resumed 20:00 UTC
- 2026-02-02 14:55 UTC, code LUDP, resumed 15:00 UTC
- 2026-02-02 14:43 UTC, code LUDP, resumed 14:53 UTC
Fails to deliver
- : 1 shares at $1.97
- : 233 shares at $2.29
- : 1 shares at $2.17
- : 15 shares at $2.05
- : 107 shares at $2.69
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
PAVmed Inc. scorecard#
Passes 4 of the 12 checks that could be worked out: strongest in profitability (1 of 3), weakest in valuation (1 of 4). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' median39.4×P/E 39.4× against Medical Devices's median of 24.1×.
- ✓Price to book below its peers' median0.5×Price to book 0.5× against Medical Devices's median of 2.5×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-33.3%Free cash flow is -33.3% of the market value.
- ✗Earnings yield above the 10-year Treasury yield2.5%Earnings yield 2.5% against the 10-year Treasury's 5.15% on 2026-11-13.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-5.63 vs 14.90Diluted EPS -5.63 in fiscal 2025 against 14.90 the year before (report's currency).
- ✓Net income higher than five years earlier$0 M$0 M in fiscal 2025 against -$34 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 3
- ✓Profitable in the newest year$0 MNet income $0 M in fiscal 2025.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%2.5%2.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.2×Current ratio 0.17 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year-69.2%Diluted shares down 69.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
PAVmed Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.1−97.6%100% | 3.0+20.0%100% | 2.5+563%100% | 0.4−24.6%100% | 0.5—100% | — | — | — | — | — | |
| Cost of revenue | 0.2−95.5%307% | 4.8−24.6%161% | 6.4+77.6%257% | 3.6+518%959% | 0.6—117% | — | — | — | — | — | |
| Gross profit | — | — | — | — | −0.1—−17.0% | — | — | — | — | — | |
| Research and development | 4.5−24.3%6327% | 5.9−58.4%198% | 14−43.7%571% | 25r26+27.7%6721% | 20+81.0%3969% | 11+65.4%— | 6.6r6.6+55.9%— | 4.3+62.2%— | 2.6r2.6+52.5%— | 1.7—— | |
| Selling and marketing | 0.9−92.1%1292% | 12−33.9%388% | 18−9.0%703% | 19+117%5124% | 8.9+219%1779% | 2.8—— | — | — | — | — | |
| General and administrative | 16−33.7%22887% | 25−20.8%817% | 31−25.3%1238% | 41r41+62.9%10984% | 25r26+165%5084% | 9.6r12+25.2%— | 7.7r7.7+21.5%— | 6.3+16.6%— | 5.4r5.4+37.7%— | 3.9—— | |
| Operating expenses | — | — | — | — | 54+133%10862% | 23+63.4%— | 14r14+35.3%— | 11+31.5%— | 8.0+42.2%— | 5.7—— | |
| Total costs and expenses | 22−53.9%30813% | 47−33.4%1583% | 71−22.1%2850% | 91r91+66.6%24261% | 55—10979% | — | — | — | — | — | |
| Operating income | −22—−30713% | −44—−1483% | −69—−2752% | −91r−91—−24161% | −54—−10879% | −23—— | −14r−14—— | −11—— | −8.0—— | −5.7—— | |
| Interest and finance income | 0.0−88.6%40.8% | 0.3—8.5% | — | — | — | — | — | — | — | — | |
| Interest expense and finance costs | 0.0−53.3%29.6% | 0.0−92.4%1.5% | 0.6−54.0%23.6% | 1.3r1.3—340% | — | 0.1r53+60.6%— | 0.0r0.0−98.6%— | 2.4+230%— | 0.7—— | — | |
| Other non-operating income (expense) | 19−73.5%27235% | 73—2430% | −10—−419% | −12r−12—−3223% | −1.7—−347% | −13—— | −3.0r−3.0—— | −7.6—— | −1.5—— | — | |
| Income before tax | −2.5−109%−3477% | 28—948% | −79—−3171% | −103—−27384% | −56—−11225% | −36—— | −17r−17—— | −18—— | −9.5—— | −5.7—— | |
| Income tax | 0—0.0% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Net income including minority interests | −2.5−109%−3477% | 28—948% | −79—−3171% | −103—−27384% | −56—−11225% | −36—— | −17r−17—— | −18r0.2—— | — | — | |
| Minority interests' share of net income | −2.9—−4042% | −11—−379% | −15—−604% | −14—−3781% | −5.8—−1156% | −1.6—— | −0.8r−0.8—— | −0.2—— | — | — | |
| Net income attributable to shareholders | 0.4−99.0%565% | 40—1326% | −64—−2567% | −89—−23603% | −50—−10069% | −34—— | −16r−16—— | −18—— | −9.5—— | −5.7—— | |
| Earnings per share, basic | -5.63−106%— | 99.15r3.30—— | -9.16—— | -15.03r-1.00—— | -0.65—— | -0.72—— | -0.54—— | -0.81—— | -0.71—— | -0.44—— | |
| Earnings per share, diluted | -5.63−138%— | 14.90r0.50—— | -9.16—— | -15.03—— | -0.65—— | -0.72—— | -0.54—— | -0.81—— | -0.71—— | -0.44—— | |
| Shares, weighted average (basic) | 0.7+108%— | 0.3r9.7−95.5%— | 7.2+21.8%— | 5.9r89−92.3%— | 78—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 0.7−69.2%— | 2.2r65−69.9%— | 7.2+21.8%— | 5.9−92.3%— | 78+63.4%— | 47+57.1%— | 30+35.6%— | 22+65.1%— | 13+4.0%— | 13—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 1.5+29.8%4.0% | 1.2−94.0%3.9% | 20−50.6%59.3% | 40−48.6%73.6% | 77+348%88.8% | 17+177%87.2% | 6.2r6.2−24.4%85.9% | 8.2+436%96.8% | 1.5+162%93.6% | 0.6—67.3% | |
| Receivables | 0.0−16.7%0.0% | 0.0−70.5%0.1% | 0.1+259%0.2% | 0.0−91.5%0.0% | 0.2—0.2% | — | — | — | — | — | |
| Inventory | — | — | 0.3+150%0.8% | 0.1—0.2% | — | — | — | — | — | — | |
| Other current assets | 1.0+4.5%2.6% | 1.0−78.7%3.1% | 4.5+11.5%13.6% | 4.1r4.2−21.7%7.5% | 5.2+207%6.0% | 1.7+414%8.5% | 0.3r0.3+37.8%4.5% | 0.2+169%2.8% | 0.1−43.1%5.4% | 0.2—17.9% | |
| Current assets | 2.6+18.2%6.6% | 2.2−91.2%7.1% | 24−44.2%74.0% | 44−46.8%81.4% | 83+336%95.0% | 19+189%95.8% | 6.5r6.5−22.6%90.4% | 8.5+421%99.6% | 1.6+119%99.0% | 0.7—85.2% | |
| Property, plant and equipment | 0.1−49.0%0.2% | 0.2−91.5%0.5% | 1.8−27.3%5.4% | 2.5+54.6%4.5% | 1.6+1833%1.8% | 0.1—0.4% | — | 0.0+124%0.4% | 0.0−10.1%1.0% | 0.0—2.1% | |
| Right-of-use (leased) assets | 2.0−19.9%5.2% | 2.5−41.4%8.2% | 4.3+40.5%12.9% | 3.0—5.6% | — | — | — | — | — | — | |
| Other intangible assets | — | — | 1.4−58.7%4.3% | 3.4+69.8%6.4% | 2.0—2.3% | — | — | — | — | — | |
| Investments in associates | 34+33.1%87.9% | 26—83.6% | — | — | — | — | — | — | — | — | |
| Total assets | 39+26.6%100% | 31−7.4%100% | 33−38.6%100% | 54−37.9%100% | 87+340%100% | 20+173%100% | 7.2r7.2−14.8%100% | 8.5+418%100% | 1.6+88.4%100% | 0.9—100% | |
| Accounts payable | 0.7+3.2%1.7% | 0.7−63.2%2.1% | 1.8−33.9%5.4% | 2.7−18.0%5.0% | 3.3+11.2%3.8% | 3.0+26.1%15.0% | 2.4r2.4+35.3%32.5% | 1.7+101%20.5% | 0.9r0.9−9.1%52.7% | 0.9—109% | |
| Current liabilities | 15−58.1%38.2% | 35−34.6%116% | 54+31.5%164% | 41+445%76.3% | 7.6—8.7% | — | 12r12+8.3%164% | 11+331%129% | 2.5+114%155% | 1.2—137% | |
| Lease liabilities (non-current) | 1.7−25.5%4.3% | 2.2−24.1%7.3% | 3.0+60.3%8.9% | 1.8—3.4% | — | — | — | — | — | — | |
| Total liabilities | 17−56.2%42.5% | 38−34.0%123% | 57+32.7%173% | 43+470%79.7% | 7.6−62.7%8.7% | 20+70.5%102% | 12r12+8.3%164% | 11+144%129% | 4.5+277%274% | 1.2—137% | |
| Retained earnings | −259—−667% | −255—−832% | −294—−889% | −228—−423% | −139—−160% | −88—−446% | −54r−54—−742% | −37—−435% | −18—−1092% | −7.7—−885% | |
| Shareholders' equity | 34—87.5% | −2.5—−8.1% | −54—−163% | −9.7−116%−17.9% | 62+3152%70.9% | 1.9—9.6% | −3.8r−3.8—−52.8% | −2.3—−27.2% | −2.8—−174% | −0.3—−36.7% | |
| Minority interests | −12—−30.1% | −4.5−115%−14.8% | 30+44.6%90.0% | 21+16.1%38.2% | 18—20.4% | −2.4—−12.0% | −0.8r−0.8—−11.2% | −0.2—−1.9% | — | — | |
| Total equity | 22—57.5% | −7.0—−22.9% | −24−320%−72.5% | 11−86.2%20.3% | 79—91.3% | −0.5—−2.4% | −4.6r−4.6—−64.1% | −2.5r−2.5—−29.1% | −2.8—−174% | −0.3—−36.7% | |
| Total liabilities and equity | 39+26.6%100% | 31−7.4%100% | 33−38.6%100% | 54−37.9%100% | 87+340%100% | 20+173%100% | 7.2r7.2−14.8%100% | 8.5+418%100% | 1.6+88.4%100% | 0.9—100% | |
| Shares outstanding | 0.9+149%— | 0.4r11−95.6%— | 8.6+36.2%— | 6.3r95−92.7%— | 86+35.3%— | 64+57.7%— | 40r40+49.1%— | 27+86.5%— | 15+9.2%— | 13—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.1−91.2%148% | 1.2−59.1%39.9% | 2.9+19.3%117% | 2.5+987%652% | 0.2—45.2% | — | — | — | — | — | |
| Share-based compensation | 1.7−73.5%2404% | 6.4−42.1%215% | 11−43.0%446% | 20+30.1%5181% | 15+634%3002% | 2.0+30.1%— | 1.6r1.6+27.9%— | 1.2+17.2%— | 1.0+40.2%— | 0.7—— | |
| Cash from operating activities | −5.2—−7332% | −34—−1118% | −52—−2081% | −71—−18829% | −41—−8118% | −22—— | −13r−13—— | −8.8—— | −6.6—— | −4.5—— | |
| Capital expenditure | −0.0—−43.7% | −0.1—−1.8% | −0.2—−9.7% | −1.5—−408% | −1.5—−294% | −0.1—— | −0.0r−0.0—— | −0.0—— | −0.0—— | −0.0—— | |
| Acquisitions, net of cash acquired | — | — | — | −3.2—−849% | −2.2—−449% | — | — | — | — | — | |
| Cash from investing activities | −0.0—−43.7% | −16−2235%−539% | 0.8—30.3% | −4.7—−1257% | −3.7—−743% | −0.1—— | −0.0r−0.0—— | −0.0—— | −0.0—— | −0.0—— | |
| Debt issued | — | — | — | — | — | — | — | — | 7.5—— | — | |
| Debt repaid | — | — | — | — | — | — | −6.1—— | — | — | — | |
| Shares issued | — | 1.6+4.2%53.3% | 1.5+1841%61.3% | 0.1−99.9%21.0% | 55+243%11003% | 16+196%— | 5.4r5.5—— | — | — | — | |
| Shares bought back | — | — | — | — | — | — | −0.1—— | — | — | — | |
| Cash from financing activities | 5.6−82.1%7873% | 31+0.4%1043% | 31−18.4%1247% | 38−63.4%10136% | 104+216%20862% | 33+190%— | 11r11−26.6%— | 16+105%— | 7.6+76.1%— | 4.3—— | |
| Change in cash | 0.4—497% | −18—−615% | −20—−804% | −38−163%−9951% | 60+444%12000% | 11—— | −2.0r−2.0−130%— | 6.7+604%— | 0.9—— | −0.2—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.1−89.0%100% | 0.0+450%100% | 0.0+175%100% | 0.1*—100% | 0.0−99.5%100% | 0.0−99.4%100% | 0.0−99.2%100% | 0*−100%— | 1.0+26.4%100% | 1.0—100% | 1.0—100% | 1.0*—100% | 0.8—100% | |
| Cost of revenue | 0.4−76.2%321% | 0.1+198%370% | 0.1+169%441% | 0.1*+77.1%163% | 0.1−96.0%1100% | 0.0−97.5%683% | 0.0−97.9%450% | 0.0*−97.0%— | 1.4−22.4%138% | 1.7—167% | 1.7—174% | 1.6*—154% | 1.8—225% | |
| Research and development | 6.4+62.3%5688% | 2.1+162%6264% | 1.4+76.4%6309% | 1.8*+127%3515% | 1.1−29.4%21760% | 0.8−51.9%13167% | 0.8−59.5%9838% | 0.8*−77.6%— | 1.5−51.2%154% | 1.6—164% | 1.9—194% | 3.6*—343% | 3.2—400% | |
| Selling and marketing | 0.9−75.1%787% | 0.2−2.3%652% | 0.2−12.6%982% | 0.2*+60.6%479% | 0.2−93.1%4020% | 0.2−94.8%3667% | 0.2−94.3%3088% | 0.2*−96.7%— | 2.9−27.3%292% | 4.2—424% | 4.3—431% | 4.7*—447% | 4.0—508% | |
| General and administrative | 19+1.7%17147% | 4.7+26.7%14094% | 6.4+45.0%28891% | 4.7*+12.1%9025% | 3.5−47.3%70100% | 3.7−47.6%61167% | 4.4−34.4%54800% | 4.2*−40.4%— | 6.6−3.0%665% | 7.0—701% | 6.7—668% | 7.0*—670% | 6.9—867% | |
| Total costs and expenses | 27−4.0%23943% | 7.1+49.4%21379% | 8.1+47.7%36623% | 6.9*+31.9%13183% | 4.8−61.4%96980% | 4.7−67.8%78683% | 5.5−63.8%68175% | 5.2*−70.2%— | 13−22.9%1257% | 15—1466% | 15—1505% | 17*—1662% | 16—2063% | |
| Operating income | −27—−23843% | −7.0—−21279% | −8.0—−36523% | −6.8*—−13083% | −4.8—−96880% | −4.7—−78583% | −5.4—−68075% | −5.2*—— | −12—−1158% | −14—−1368% | −14—−1404% | −16*—−1562% | −16—−1963% | |
| Interest and finance income | — | 0.0+25.0%30.3% | 0.0+138%86.4% | — | — | 0.0—133% | 0.0—100% | — | — | — | — | — | — | |
| Interest expense and finance costs | — | 0.0−92.3%6.1% | 0.0−88.5%13.6% | — | 0.0−33.3%160% | 0.0+136%433% | 0.0+62.5%325% | 0.0*−63.2%— | 0.0−92.5%1.2% | 0.0—1.1% | 0.0—1.6% | 0.0*—1.8% | 0.2—20.1% | |
| Other non-operating income (expense) | 10−89.2%9173% | 0.4—1285% | 7.0−71.0%31686% | 4.0*−36.1%7781% | −1.2−102%−23340% | −7.6—−126817% | 24—300863% | 6.3*—— | 72—7229% | −1.2—−123% | −4.5—−448% | −1.0*—−97.7% | −6.2—−787% | |
| Income before tax | −16−124%−14670% | −6.6—−19994% | −1.1−106%−4836% | −2.8*−341%−5302% | −6.0−110%−120220% | −12—−205400% | 19—232788% | 1.1*—— | 61—6071% | −15—−1491% | −19—−1851% | −17*—−1659% | −22—−2750% | |
| Income tax | — | 0—0.0% | 0—0.0% | — | — | 0—0.0% | 0—0.0% | — | — | — | — | — | — | |
| Net income including minority interests | −16−124%−14670% | −6.6—−19994% | −1.1−106%−4836% | −2.8*−341%−5302% | −6.0−110%−120220% | −12—−205400% | 19—232788% | 1.1*—— | 61—6071% | −15—−1491% | −19—−1851% | −17*—−1659% | −22—−2750% | |
| Minority interests' share of net income | −4.3—−3875% | −1.2—−3679% | −1.0—−4564% | −1.5*—−2873% | −0.6—−12560% | −0.4—−6717% | −0.3—−4313% | −0.3*—— | −3.7—−369% | −4.1—−409% | −3.3—−330% | −3.4*—−321% | −4.1—−516% | |
| Net income attributable to shareholders | −12−117%−10795% | −5.4—−16315% | −0.1−100%−273% | −1.3*−188%−2429% | −5.4−108%−107660% | −12—−198683% | 19—237100% | 1.4*—— | 64—6440% | −11—−1083% | −15—−1521% | −14*—−1338% | −18—−2234% | |
| Earnings per share, basic | — | -0.87—— | -4.42−112%— | — | -0.29−105%— | -22.08r-0.74—— | 38.26r1.28—— | — | 6.43—— | -1.19—— | -2.62—— | — | -2.38r-0.16—— | |
| Earnings per share, diluted | — | -0.87—— | -4.42−144%— | — | -0.29−120%— | -22.08r-0.74—— | 10.10r0.34—— | — | 1.44—— | -1.19—— | -2.62—— | — | -2.38r-0.16—— | |
| Shares, weighted average (basic) | 6.3+940%— | 6.3+940%— | 1.6+242%— | — | 22+115%— | 0.6r18−93.4%— | 0.5r14−94.7%— | — | 10+34.1%— | 9.2—— | 8.7—— | — | 7.5r112—— | |
| Shares, weighted average (diluted) | 6.3+940%— | 6.3+940%— | 1.6−9.5%— | — | 22−51.5%— | 0.6r18−93.4%— | 1.7r52−79.9%— | — | 44+496%— | 9.2—— | 8.7—— | — | 7.5r112—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 3.8—9.4% | 3.8−5.5%9.4% | 6.5+139%14.2% | 1.5+29.8%4.0% | 3.1+306%8.2% | 4.0−84.3%9.1% | 2.7−89.4%5.1% | 1.2−94.0%3.9% | 0.8−97.1%2.5% | 25—64.7% | 26—68.5% | 20—59.3% | 26—62.8% | |
| Receivables | 0.0—0.0% | 0.0+433%0.0% | 0.0+133%0.0% | 0.0−16.7%0.0% | 0.0−81.3%0.0% | 0.0−98.6%0.0% | 0.0−86.6%0.0% | 0.0−70.5%0.1% | 0.0−55.6%0.1% | 0.2—0.6% | 0.1—0.2% | 0.1—0.2% | 0.0—0.1% | |
| Inventory | — | — | — | — | — | — | — | — | 0.0—0.0% | 0.7—1.7% | 0.4—1.1% | 0.3—0.8% | — | |
| Other current assets | 1.1—2.6% | 1.1−28.6%2.6% | 0.9+0.4%2.1% | 1.0+4.5%2.6% | 1.1−19.2%2.9% | 1.5−61.0%3.4% | 0.9−73.9%1.8% | 1.0−78.7%3.1% | 1.3−77.7%4.4% | 3.8—9.6% | 3.6—9.6% | 4.5—13.6% | 6.0—14.3% | |
| Current assets | 4.9—12.1% | 4.9−11.5%12.1% | 7.4+104%16.3% | 2.6+18.2%6.6% | 4.2+96.8%11.0% | 5.5−81.8%12.5% | 3.6−87.7%6.9% | 2.2−91.2%7.1% | 2.1−93.4%7.0% | 30—76.6% | 30—79.4% | 24—74.0% | 32—77.3% | |
| Property, plant and equipment | 0.1—0.2% | 0.1−27.0%0.2% | 0.1−30.7%0.2% | 0.1−49.0%0.2% | 0.1−62.5%0.2% | 0.1−92.5%0.2% | 0.1−92.9%0.2% | 0.2−91.5%0.5% | 0.2−88.1%0.7% | 1.3—3.4% | 1.6—4.3% | 1.8—5.4% | 1.8—4.3% | |
| Right-of-use (leased) assets | 1.7—4.3% | 1.7−23.0%4.3% | 1.9−21.3%4.1% | 2.0−19.9%5.2% | 2.1−18.6%5.6% | 2.3−60.9%5.1% | 2.4−38.8%4.5% | 2.5−41.4%8.2% | 2.6−43.9%8.6% | 5.8—14.6% | 3.9—10.4% | 4.3—12.9% | 4.7—11.1% | |
| Other intangible assets | — | — | — | — | — | — | — | — | — | 0.9—2.4% | 1.1—2.8% | 1.4—4.3% | 1.9—4.6% | |
| Investments in associates | 33—83.3% | 33−7.0%83.3% | 36−22.8%79.3% | 34+33.1%87.9% | 32+23.9%83.0% | 36—82.0% | 47—88.3% | 26—83.6% | 26—83.5% | — | — | — | — | |
| Total assets | 40—100% | 40−8.4%100% | 45−14.0%100% | 39+26.6%100% | 38+24.6%100% | 44+11.4%100% | 53+41.8%100% | 31−7.4%100% | 31−27.3%100% | 39—100% | 37—100% | 33—100% | 42—100% | |
| Accounts payable | 1.1—2.6% | 1.1+173%2.6% | 1.0+166%2.2% | 0.7+3.2%1.7% | 0.3−26.5%0.9% | 0.4−68.6%0.9% | 0.4−75.2%0.7% | 0.7−63.2%2.1% | 0.5−78.5%1.5% | 1.2—3.1% | 1.5—4.0% | 1.8—5.4% | 2.2—5.2% | |
| Current liabilities | 4.1—10.2% | 4.1−61.1%10.2% | 3.7−62.5%8.1% | 15−58.1%38.2% | 10−72.2%27.5% | 11−80.3%23.9% | 9.8−82.2%18.5% | 35−34.6%116% | 38−31.1%123% | 53—135% | 55—148% | 54—164% | 55—130% | |
| Lease liabilities (non-current) | 1.4—3.5% | 1.4−29.0%3.5% | 1.5−27.9%3.4% | 1.7−25.5%4.3% | 1.8−23.4%4.8% | 2.0−57.8%4.5% | 2.1−25.0%4.0% | 2.2−24.1%7.3% | 2.4−28.8%7.8% | 4.7—11.8% | 2.8—7.6% | 3.0—8.9% | 3.3—8.0% | |
| Total liabilities | 21—52.0% | 21+67.6%52.0% | 20+71.8%45.0% | 17−56.2%42.5% | 12−69.2%32.3% | 12−78.5%28.4% | 12−79.4%22.5% | 38−34.0%123% | 40−31.0%131% | 58—147% | 58—155% | 57—173% | 58—138% | |
| Retained earnings | −265—−658% | −265—−658% | −259—−570% | −259—−667% | −257—−675% | −251—−571% | −237—−449% | −255—−832% | −256—−839% | −321—−814% | −310—−831% | −294—−889% | −279—−663% | |
| Shareholders' equity | 35—87.2% | 35−6.6%87.2% | 40−12.2%87.0% | 34—87.5% | 33—85.4% | 38—85.5% | 45—85.2% | −2.5—−8.1% | −4.9—−15.9% | −74—−188% | −69—−185% | −54—−163% | −43—−103% | |
| Minority interests | −16—−39.1% | −16—−39.1% | −15—−32.0% | −12—−30.1% | −10.0—−26.2% | −9.4−117%−21.3% | −6.1−113%−11.5% | −4.5−115%−14.8% | −4.5−116%−14.8% | 55—140% | 48—129% | 30—90.0% | 27—65.3% | |
| Total equity | 19—48.0% | 19−31.4%48.0% | 25−35.8%55.0% | 22—57.5% | 23—59.2% | 28—64.2% | 39—73.7% | −7.0—−22.9% | −9.4—−30.7% | −19—−47.3% | −21—−55.2% | −24—−72.5% | −16—−37.7% | |
| Total liabilities and equity | 40—100% | 40−8.4%100% | 45−14.0%100% | 39+26.6%100% | 38+24.6%100% | 44+11.4%100% | 53+41.8%100% | 31−7.4%100% | 31−27.3%100% | 39—100% | 37—100% | 33—100% | 42—100% | |
| Shares outstanding | 6.3—— | 6.3−68.9%— | 6.3−62.6%— | 0.9+149%— | 23+116%— | 20+111%— | 17+89.3%— | 0.4r11−95.6%— | 11−91.1%— | 9.6—— | 8.9—— | 8.6—— | 120—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−78.8%70.5% | 0.0*−13.6%57.6% | 0.0−53.5%90.9% | 0.0*−73.9%34.6% | 0.0*−90.8%440% | 0.0*−92.8%367% | 0.0−92.7%538% | 0.1*−90.5%— | 0.2*−67.5%23.8% | 0.3*—30.5% | 0.6—58.6% | 0.7*—69.1% | 0.7*—92.7% | |
| Share-based compensation | 1.7−54.4%1530% | 0.9+466%2779% | 0.2−80.4%827% | 0.2*−68.3%446% | 0.4−80.2%7660% | 0.2−91.5%2700% | 0.9−50.6%11625% | 0.7*−62.8%— | 1.9−14.0%193% | 1.9—190% | 1.9—188% | 2.0*—188% | 2.2—284% | |
| Cash from operating activities | −7.7—−6902% | −2.7*—−8070% | −2.6—−11909% | −1.6*−1750%−2983% | −0.9*—−17920% | −1.2*—−19633% | −1.6—−19763% | 0.1*—— | −8.9*—−888% | −12*—−1166% | −13—−1311% | −12*—−1132% | −11*—−1402% | |
| Capital expenditure | −0.1—−46.4% | −0.0*—−39.4% | −0.0—−100% | −0.0*—−26.9% | −0.0*—−60.0% | −0.0*—−133% | −0.0—−75.0% | −0.0*—— | −0.0*—−0.6% | −0.0*—−0.3% | −0.0—−4.2% | −0.2*—−17.4% | −0.0*—−2.3% | |
| Cash from investing activities | −0.1—−46.4% | −0.0*—−39.4% | −0.0—−100% | −0.0*—−26.9% | −0.0*—−60.0% | −0.0*—−133% | −0.0—−75.0% | −0.0*—— | −16*—−1614% | −0.0*—−0.3% | −0.0—−4.2% | −0.2*—−17.4% | −0.0*—−2.3% | |
| Shares issued | — | — | — | — | −1.6r0*−681%−32980% | 1.6r0*+733%27483% | 0.8+7.0%10513% | 0.3*−10.1%— | 0.3*—28.4% | 0.2*—19.8% | 0.8—78.6% | 0.4*—35.0% | 0*—0.0% | |
| Cash from financing activities | 7.6+21.8%6752% | 0*−100%0.0% | 7.6+144%34382% | 0*−100%0.0% | −0.0*−101%−40.0% | 2.5*−78.6%41500% | 3.1−83.7%38775% | 0.3*−93.8%— | 0.3*−19.3%28.4% | 12*—1162% | 19—1905% | 5.3*—504% | 0.4*—44.5% | |
| Change in cash | −0.2—−196% | −2.7*−305%−8109% | 4.9+225%22373% | −1.6*−473%−3010% | −0.9*—−18020% | 1.3*—21733% | 1.5−74.3%18938% | 0.4*—— | −25*—−2473% | −0.0*—−3.7% | 5.9—590% | −6.8*—−645% | −11*—−1360% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at PAVmed Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Lishan Aklog, M.D | $1.0 M | $992 K | $596 K | $3 |
| 2024Lishan Aklog, M.D | $1.4 M | $798 K | $1.1 M | $2 |
| 2023Lishan Aklog, M.D | $953 K | $883 K | $627 K | $11 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at PAVmed Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 2 · Auditor changed 1 · Directors and officers 3 · Material agreement 5 · Agreement ended 1 · New debt 1 · Unregistered share sale 4 · Shareholder rights changed 5 · Bylaws or fiscal year changed 5 · Shareholder vote 5 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Material agreementShareholder rights changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Material agreementAgreement endedNew debtUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Delisting noticeUnregistered share saleShareholder rights changed | 8-K | |
| Delisting noticeUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 22, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2026 | $30 M | Private placement after listing | $10 to $50 million | 14 | equity, options | SEC |
| Jan 2025 | $3 M | Private placement after listing | $2 to $10 million | 1 | equity | SEC |
| Aug 2020 | $8 M | Private placement after listing | $2 to $10 million | 1 | debt, options | SEC |
| Apr 2020 | $4 M | Private placement after listing | $2 to $10 million | 1 | debt, options | SEC |
| Nov 2019 | $14 M | Private placement after listing | $10 to $50 million | 2 | debt, options | SEC |
| Dec 2018 | $8 M | Private placement after listing | $2 to $10 million | 1 | debt, options | SEC |
| Jan 2017 | $2 M | Private placement after listing | Under $2 million | 13 | equity, debt | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at PAVmed Inc.#
2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $120 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Manager, Clinical Research Data [00099460]Clinical Research Coordinators | 1 | $110 K |
| Senior Manufacturing Engineer [00111112]Manufacturing Engineers | 1 | $130 K |
Where: New York, NY 2
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 2 | 2 | $120 K | 2 |
| FY2025 | 1 | 1 | $112 K | 1 |
| FY2024 | 1 | 1 | $110 K | 1 |
| FY2022 | 2 | 2 | $80 K | 2 |
| FY2021 | 1 | 1 | $125 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as PAVmed Inc.
How PAVmed Inc. compares in Medical Devices
- Market cap$16 M · higher than 9% of 142
- Revenue growth20.0% · higher than 74% of 104
- P/E ratio39.4× · lower than 33% of 47
- Price / book0.5× · lower than 97% of 99
- FCF yield-33.3% · higher than 24% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| PAVmed Inc.🇺🇸 | $16 M | 39.4× | — | +20.0% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 27, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at PAVmed Inc.? Verify and update this profile — free
Show PAVmed Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.